Publications
Publications
Show Results For
- All HBS Web
(935)
- Faculty Publications (482)
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- February 1996
- Case
Chadwick, Inc.: The Balanced Scorecard (Abridged)
By: Robert S. Kaplan
The pharmaceutical division of a diversified company has been asked to develop a Balanced Scorecard. Research and development projects take about ten years to bring a new product to the marketplace and the division depends on good relations and active feedback from its... View Details
- January 1996
- Case
Biogen, Inc.: rBeta Interferon Manufacturing Process Development
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing... View Details
- November 1995 (Revised March 2004)
- Case
Massachusetts General Hospital: CABG Surgery (A)
By: Steven C. Wheelwright and James Weber
A cross-functional team at Massachusetts General Hospital tries to reengineer the service delivery process (the "care path") for heart bypass surgery (CABG) in order to shorten hospital stays (and lower costs) while maintaining/enhancing the quality of care provided. View Details
Keywords: Health Care and Treatment; Medical Specialties; Business Processes; Mission and Purpose; Product Positioning; Product Marketing; Management Practices and Processes; Customer Satisfaction; Service Delivery; Service Operations; Fair Value Accounting; Ethics; Pharmaceutical Industry; Pharmaceutical Industry; Massachusetts
- September 1995
- Case
Ares-Serono
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details
Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; Europe
- August 1995
- Teaching Note
Eli Lilly and Company: The Flexible Facility Decision (1993) TN
By: Gary P. Pisano
Teaching Note for (9-694-074). View Details
Keywords: Pharmaceutical Industry
- March 1995 (Revised January 1996)
- Teaching Note
Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal TN
By: David J. Collis
Teaching Note for (9-795-040). View Details
- February 1995 (Revised March 1995)
- Teaching Note
Astra/Merck Group TN
Teaching Note for (9-594-045). View Details
Keywords: Pharmaceutical Industry
- January 1995 (Revised November 2021)
- Case
Portfolio Planning at Ciba-Geigy and the Newport Investment Proposal
By: David J. Collis and Elizabeth Wynne Johnson
Covers the history of portfolio planning at CIBA-GEIGY, a leading Swiss chemical and pharmaceutical company, beginning with the introduction of the process in the mid-1980s. The discussion extends to the application of portfolio planning techniques to a specific... View Details
- December 1994 (Revised March 1996)
- Case
Ciba Consumer Pharmaceuticals' Acutrim: Challenges and Opportunities in Today's Diet Industry
By: Nancy F. Koehn and Rebecca Voorheis
Since its introduction in 1983, Acutrim has been a major player in the U.S. appetite suppressant market and in the broader diet industry. This case focuses on the strategic, regulatory, marketing, and financial challenges this product and the rapidly changing diet... View Details
- August 1994
- Teaching Note
Yamanouchi Pharmaceutical Co., Ltd. TN
By: Robin Cooper and Robert S. Kaplan
Keywords: Pharmaceutical Industry
- March 1994 (Revised March 1995)
- Case
Astra/Merck Group
By: Frank V. Cespedes and Marie Bell
Astra/Merck (A/M), originally a joint venture of AB Astra and Merck & Co., is preparing to be an independent company in 1993. Since the company does not engage in basic research and development of drugs, it is essentially a distribution organization. Fundamental to... View Details
- March 1994 (Revised April 1994)
- Case
Eli Lilly and Co.: The Flexible Facility Decision--1993
By: Gary P. Pisano
In 1993, Eli Lilly is preparing to build manufacturing capacity for three new pharmaceutical products that it expects to launch in 1996. Management wrestles with a decision of whether to add specialized manufacturing capacity or flexible capacity. This question touches... View Details
- October 1993 (Revised February 1995)
- Case
Dendrite International
By: Frank V. Cespedes and Marie Bell
Dendrite International is a $23 million (1992 revenues) supplier of sales automation software to pharmaceuticals companies in Europe, Japan, and the United States. The firm's strategy has depended on being a full-service supplier to multinational firms. Impending... View Details
- September 1993
- Case
Manufacturing at ALZA: The Right Prescription? (A)
ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner... View Details
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (B)
ALZA, a drug delivery company, must decide what and for whom to manufacture. In the past, it has licensed to pharmaceutical companies its patented system for the slow release of drugs into the human system. Therefore the company has little experience in choice of drug... View Details
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details